Research & DevelopmentChina based Lynk Pharma raises $50M in series B...

China based Lynk Pharma raises $50M in series B funding round

-

The Chinese pharmaceutical R&D company, Lynk Pharmaceuticals Co. Ltd., has successfully raised $50 million in Series B funding round.

It was founded in 2018 by the Chairperson and CEO, Dr. Zhao-Kui (ZK) Wan, with the aim to develop FIC/BIC small molecule drugs globally for different cancers, autoimmune and inflammatory diseases.

Within the three and half years of its existence, the pharmaceutical R&D company has managed to receive IND approvals in China and U.S. for three of its products, initiated worldwide clinical development efforts and completed ex-Chinese rights out-license of LNK01001 to a U.S. company and also in-license of the top-tier RAS program of Japan’s Kobe University and RIKEN in 2020.  

The Series B financing round was headed by Lilly Asia Ventures (LAV) as a lead investor. New Alliance Capital and Hangzhou HEDA Biological Medicine Venture Capital Partnership (L.L.P.), together with its original shareholders Legend Capital and Med-Fine Capital, also took part for the cause.       

The company now plans to utilize these funds for phase I and II clinical trials of certain projects in its R&D pipeline. Moreover, these funds will be used for extending international business of the company Lynk Pharmaceuticals upholding international collaborations with various companies and aiding preclinical development of new projects.

Life Sciences Voice Logo mobile
+ posts

Latest news

Can AI Predict Regulatory Outcomes in Pharma and Biotech?

Executive Summary AI can partially predict regulatory outcomes in pharma and biotech, but it cannot replace regulatory judgment. In 2026,...

Market Access Challenges in Pharmaceuticals: Pricing, Policy, and Payer Pressure

Executive Summary Market access challenges in pharmaceuticals in 2026 are defined by increasing pricing pressure, evolving policy frameworks, and more...

Why Is Market Access Becoming More Difficult for Pharma Companies?

Executive Summary Market access is becoming more difficult for pharma companies in 2026 due to a convergence of pricing pressure,...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you